Condition: Radiation-Induced Xerostomia and Hyposalivation · Sponsor: RiboX Therapeutics Ltd.
This is a first-in-human clinical study to evaluate the safety, tolerability and efficacy of RXRG001 administered in the ducts of the parotid glands in adult patients with radiation-induced xerostomia (dry mouth) and hyposalivation (reduced saliva production). In Part 1 of the study (open-label, single-arm), patients will receive unilateral administrations of RXRG001 in 3 single ascending dose cohorts and in 3 multiple ascending dose cohorts. Part 2 of the study has a randomized, double-blind, placebo-controlled design. Patients will receive bilateral administrations of RXRG001 in 3 multiple ascending dose cohorts.
This description comes directly from the study's public registry record.
RiboX Therapeutics Ltd. · 617-999-8257 · RiboX-SPRINX1-RX-RIX-CS101-Study-Mailbox@ribox-tx.com
Always discuss trial participation with your own doctor first.
| University of Iowa Hospitals and Clinics | Iowa City, Iowa, United States | Recruiting |
| John Hopkins University, Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
| NYU Langone Medical Center | New York, New York, United States | Recruiting |
| Penn Medicine - Otorhinolaryngology - Head and Neck Surgery Perelman | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06714253